Albumin-bound paclitaxel single-day dosing caused a higher incidence of CIPN ≥ B grade in sarcopenic patients (75.0%) versus non-sarcopenic (62.5%) with P=0.042.
Observational (n=52)
No
Does sarcopenia increase the incidence and severity of chemotherapy-induced peripheral neuropathy in patients undergoing albumin-bound paclitaxel chemotherapy?
Sarcopenia increases the risk and severity of peripheral neuropathy in patients receiving albumin-bound paclitaxel, highlighting the potential need for individualized dosing based on body composition.
Effect estimate: P=0.042 for CIPN ≥ B grade incidence comparison in Group A sarcopenia vs non-sarcopenia
Absolute Event Rate: 75% vs 62.5%
p-value: p=0.042
Sarcopenia significantly increases the incidence and severity of CIPN in patients undergoing nab-PTX-based chemotherapy. This association may be attributed to the effectively higher dose of nab-PTX per kilogram of lean body mass in patients with sarcopenia, despite the absence of a direct correlation between L3SMI and measured blood drug concentrations. These findings highlight the importance of body composition assessment prior to chemotherapy, as patients with sarcopenia may require enhanced monitoring for CIPN or individualized dosing considerations.
Jiang et al. (Fri,) conducted a observational in Patients with malignant tumors (lung cancer, esophageal carcinoma, cervical cancer, ovarian cancer) receiving nab-paclitaxel based chemotherapy (n=52). Albumin-bound paclitaxel (nab-PTX) administered as single dose 260 mg/m2 on day 1 or split dose 130 mg/m2 on days 1 and 8 vs. Comparison between single-dose (Group A) and split-dose (Group B) regimens and between sarcopenia and non-sarcopenia groups was evaluated on Incidence of chemotherapy-induced peripheral neuropathy (CIPN) ≥ grade B and severe CIPN (≥ grade C) assessed by Taxane Patient Neurotoxicity Questionnaire before third chemotherapy cycle (P=0.042 for CIPN ≥ B grade incidence comparison in Group A sarcopenia vs non-sarcopenia, p=0.042). Albumin-bound paclitaxel single-day dosing caused a higher incidence of CIPN ≥ B grade in sarcopenic patients (75.0%) versus non-sarcopenic (62.5%) with P=0.042.